Tired T cells hamper cancer treatment, but could be a boon for diabetes drug

Healthy human T cell. Image: NIAID

While T cell exhaustion can hinder cancer treatments, a Benaroya Research Institute-led team has discovered that T cell fatigue may potentially boost therapies for diabetes and other autoimmune diseases.

Immune T cells burn out and become less effective when they are overworked, so scientists working on cancer immunotherapies are seeking to bypass this phenomenon. But a new study found that T cells with similar qualities to fatigued T cells are associated with a positive response to the diabetes drug Teplizumab.

The researchers, from the Benaroya Research Institute, the Immune Tolerance Network and Yale University, studied 74 patients with Type 1 diabetes, 49 of whom were treated with Teplizumab. The remaining 25 patients served as a control group.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The team found that patients who were particularly responsive to the drug had memory T cells that shared characteristics with tired T cells, including high levels of the transcription factor EOMES and multiple inhibitory receptors, according to the study. The findings prompted the researchers to conclude that T cell exhaustion may contribute to successful immune interventions for Type 1 diabetes.

Teplizumab has had a bumpy ride: Eli Lilly in-licensed the drug from MacroGenics for a whopping $41 million only to pull the plug on its Phase III program when it failed a late-stage trial in 2010. Despite the failure, the anti-CD3 monoclonal antibody found success three years later, proving “strikingly effective” at preserving insulin-producing cells in a trial of 52 newly diagnosed Type 1 diabetics, most of whom were younger than 14.

The study’s results suggest yet another avenue for Teplizumab to rise from the ashes: Weary T cells could be a target for therapies against diabetes and other autoimmune diseases.

Meanwhile, George Washington University researchers have tapped into another facet of T cells in autoimmune disease. In August, they identified transcription factors as a “vital component” in determining the function of a T cell, that is, whether it will become a killer or helper T cell. They hypothesized that transcription factors could be manipulated to skew the T cell ratio in favor of killer cells, thus reinforcing the immune system against autoimmune diseases.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.